Human Immunodeficiency Virus Type 1 DNA Decay Dynamics With Early, Long-term Virologic Control of Perinatal Infection

Background. Early antiretroviral therapy (ART) limits proviral reservoirs, a goal for human immunodeficiency virus type 1 (HIV-1) remission strategies. Whether this is an immediate or long-term effect of virologic suppression (VS) in perinatal infection is unknown. Methods. We quantified HIV-1 DNA longitudinally for up to 14 years in peripheral blood mononuclear cells (PBMCs) among 61 perinatally HIV-1-infected youths in the Pediatric HIV/AIDS Cohort Study who achieved VS at different ages. Participants in group 1 (n = 13) were <1 year of age and in group 2 (n = 48) from 1 through 5 years of age at VS. Piecewise linear mixed-effects regression models assessed the effect of age at VS on HIV-1 DNA trajectories during VS. Results. In the first 2 years following VS, HIV-1 DNA levels decreased by -0.25 (95% confidence interval [CI], -.36 to -.13) log10 copies/million PBMCs per year and was faster with early VS by age 1 year compared with after age 1 (-0.50 and -0.15 log10 copies/million PBMCs per year, respectively). Between years 2 and 14 from VS, HIV-1 DNA decayed by -0.05 (95% CI, -.06 to -.03) log10 copies/million PBMCs per year and was no longer significantly different between groups. The estimated mean half-life of HIV-1 DNA from VS was 15.9 years and was shorter for group 1 compared to group 2 at 5.9 years and 18.8 years, respectively (P = .09). Adjusting for CD4 cell counts had no effect on decay estimates. Conclusions. Early effective, long-term ART initiated from infancy leads to decay of HIV-1-infected cells to exceedingly low concentrations desired for HIV-1 remission strategies.

[1]  R. Dewar,et al.  Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy , 2016, Proceedings of the National Academy of Sciences.

[2]  M. Lichterfeld,et al.  Diversity of HIV-1 reservoirs in CD4+ T-cell subpopulations , 2016, Current opinion in HIV and AIDS.

[3]  E. Mick,et al.  Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants , 2016, PloS one.

[4]  S. Lewin,et al.  Paediatric HIV infection: the potential for cure , 2016, Nature Reviews Immunology.

[5]  S. Hughes,et al.  Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo , 2016, Proceedings of the National Academy of Sciences.

[6]  R. Phillips,et al.  Immunological biomarkers predict HIV-1 viral rebound after treatment interruption , 2015, Nature Communications.

[7]  M. Johnson,et al.  Author response: Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs , 2015 .

[8]  G. Yenokyan,et al.  Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Mellors,et al.  Early Antiretroviral Therapy in South African Children Reduces HIV-1-Infected Cells and Cell-Associated HIV-1 RNA in Blood Mononuclear Cells. , 2015, The Journal of infectious diseases.

[10]  C. Rouzioux,et al.  Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  A. Haase,et al.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption , 2015, Proceedings of the National Academy of Sciences.

[12]  D. Persaud,et al.  Very early combination antiretroviral therapy in infants: prospects for cure , 2015, Current opinion in HIV and AIDS.

[13]  D. Richman,et al.  Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. , 2014, JAMA pediatrics.

[14]  J. Mellors,et al.  HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Carrington,et al.  HIV-1 DNA predicts disease progression and post-treatment virological control , 2014, eLife.

[16]  S. Hughes,et al.  Specific HIV integration sites are linked to clonal expansion and persistence of infected cells , 2014, Science.

[17]  J. Ananworanich,et al.  Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children , 2014, AIDS.

[18]  Feng Fu,et al.  Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 , 2014, Proceedings of the National Academy of Sciences.

[19]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[20]  D. Pillay,et al.  The Immunological and Virological Consequences of Planned Treatment Interruptions in Children with HIV Infection , 2013, PloS one.

[21]  C. Rouzioux,et al.  Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. , 2013, The Journal of antimicrobial chemotherapy.

[22]  Douglas D. Richman,et al.  Highly Precise Measurement of HIV DNA by Droplet Digital PCR , 2013, PloS one.

[23]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[24]  Jerome H. Kim,et al.  Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection , 2012, PloS one.

[25]  Thierry Prazuck,et al.  Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection , 2010, AIDS.

[26]  J. Ananworanich,et al.  Response to planned treatment interruptions in HIV infection varies across childhood , 2010, AIDS.

[27]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[28]  C. Giaquinto,et al.  Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy. , 2006, The Journal of infectious diseases.

[29]  Matthew C Strain,et al.  Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. , 2005, The Journal of infectious diseases.

[30]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[31]  A. Walker,et al.  Biphasic decay of cell-associated HIV-1 DNA in HIV-1-infected children on antiretroviral therapy. , 2002, AIDS.

[32]  S. Spector,et al.  Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. , 2002, The Journal of infectious diseases.

[33]  R. Yogev,et al.  Infrequent Detection of HIV-1-Specific, But Not Cytomegalovirus-Specific, CD8+ T Cell Responses in Young HIV-1-Infected Infants1 , 2001, The Journal of Immunology.

[34]  M. Stevenson,et al.  Early Therapy of Vertical Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Control of Viral Replication and Absence of Persistent HIV-1-Specific Immune Responses , 2000, Journal of Virology.

[35]  R. Siliciano,et al.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. , 2000, The Journal of clinical investigation.

[36]  R. Lempicki,et al.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[38]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[39]  M. Badellino,et al.  Pediatric heart transplantation at St. Christopher's Hospital for Children. , 1987, The Journal of heart transplantation.